Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endogenous nitric oxide production induced by pulsed electric field modulates postharvest quality of mango.

Food research international (Ottawa, Ont.)·2026
Same author

Health effects of urgent care center entry: The case of WellNow.

Economics and human biology·2026
Same author

MR-Linac-Based SBRT for Prostate Cancer: Dosimetric Benefits for Urethral Sparing Compared to VMAT and Tomotherapy.

Cancers·2026
Same author

Methyl group donor‑resolved isotopic diagnostics reveal mechanistic diversity in UV‑driven methylation of Hg(II).

Journal of hazardous materials·2026
Same author

Microplastics inhibit oxytetracycline degradation in soils: Insights into biofilm-enhanced adsorption and microbial community shifts.

Journal of hazardous materials·2025
Same author

Aligning global mercury mitigation with climate action.

Nature communications·2025
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Oct 2, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K

Proton Therapy for Prostate Cancer: Challenges and Opportunities.

Darren M C Poon1, Stephen Wu2, Leon Ho2

  • 1Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, Hong Kong 999077, China.

Cancers
|February 25, 2022
PubMed
Summary
This summary is machine-generated.

Proton therapy (PT) offers dosimetric advantages for prostate cancer over photon therapy, but similar outcomes suggest issues with dose delivery. New technologies aim to improve PT accuracy and conformity for better clinical results.

Keywords:
magnetic resonance imagingprostateproton therapy

More Related Videos

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.9K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

15.9K

Related Experiment Videos

Last Updated: Oct 2, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.5K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.9K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

15.9K

Area of Science:

  • Radiation Oncology
  • Medical Physics
  • Oncology

Background:

  • Proton therapy (PT) demonstrates superior dosimetric advantages over photon-based external beam radiotherapy (EBRT) for localized prostate cancer.
  • However, similar clinical outcomes between PT and EBRT suggest potential issues in dose prescription or delivery accuracy.
  • Uncertainties in treatment planning and delivery can compromise the dose conformity of PT, potentially limiting its clinical benefits.

Purpose of the Study:

  • To review the challenges in proton therapy for prostate cancer and highlight emerging technologies to address them.
  • To explore how advanced PT techniques can improve treatment accuracy, dose conformity, and clinical outcomes.
  • To discuss the potential for dose escalation and hypofractionation with improved PT precision.

Main Methods:

  • Review of advanced PT technologies and techniques for improving accuracy and dose conformity.
  • Discussion of innovations in patient positioning (e.g., MRI-guidance), beam delivery (high-dose rate), and treatment verification (e.g., prompt gamma detectors).
  • Examination of advanced treatment planning systems (e.g., dual-energy photon-counting CT, Monte Carlo simulations).

Main Results:

  • Emerging PT technologies aim to minimize geometric and dosimetric uncertainties.
  • In-room MRI-guided systems and high-dose rate delivery promise enhanced accuracy and reduced motion artifacts.
  • Advanced planning and verification tools are expected to improve dose calculations and in-vivo accuracy.

Conclusions:

  • Clinical implementation of advanced PT technologies is anticipated to improve accuracy and dose conformity for prostate cancer treatment.
  • Enhanced precision may enable dose escalation, improving local control and facilitating hypofractionation.
  • These advancements could lead to better clinical outcomes and make PT more cost-effective.